Cancer Family
Neoplasm
CI-CAN-00000001Explore in graph →
Non-malignant22,971 active trials259 approved drugs4,031 evidence items
Loading cancer entity…
Cancer Family
CI-CAN-00000001Explore in graph →
Clinical trials
105,884 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT05773274 | Comparing Retreatment of 177Lu-DOTATATE PRRT Versus the Usual Treatment in Patients With Metastatic Unresectable Gastroenteropancreatic Neuroendocrine Tumors, NET RETREAT Trial | recruiting | Phase 2 | 100 | National Cancer Institute (NCI)NIH | 2 | Sep 24, 2026 | clinicaltrials |
| NCT05842044 | NSAID Use After Robotic Partial Nephrectomy(No-PAIN) | recruiting | Phase 2 | 110 | University of MiamiOTHER | 1 | Sep 24, 2026 |
| clinicaltrials |
| NCT06047379 | Safety and Efficacy of NEO212 in Patients With Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype or Brain Metastasis | recruiting | Phase 1 / Phase 2 | 134 | Neonc Technologies, Inc.INDUSTRY | 1 | Sep 24, 2026 | clinicaltrials |
| NCT06057935 | A Study of Additional Chemotherapy After Surgery for People With Malignant Peritoneal Mesothelioma | recruiting | Phase 2 | 64 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Sep 24, 2026 | clinicaltrials |
| NCT06062420 | A Platform Study of Novel Immunotherapy Combinations as First-Line Treatment in Participants With PD-L1 Positive Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck- GALAXIES H&N-202 | active not recruiting | Phase 2 | 316 | GlaxoSmithKlineINDUSTRY | 20 | Sep 24, 2026 | clinicaltrials |
| NCT06084780 | Intestinal & Multivisceral Transplantation for Unresectable Mucinous Carcinoma Peritonei (TRANSCAPE)(TRANSCAPE) | not yet recruiting | Phase 2 | 20 | Case Comprehensive Cancer CenterOTHER | 1 | Sep 24, 2026 | clinicaltrials |
| NCT06123338 | A Study of Pembrolizumab With Trastuzumab and Chemotherapy in People With Esophagogastric Cancer | recruiting | Phase 2 | 49 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Sep 24, 2026 | clinicaltrials |
| NCT06179303 | Functional Imaging in Prediction of Response to Abemaciclib for Advanced Hormone Receptor-Positive, HER2-Negative Breast Cancer | recruiting | Phase 2 | 60 | University of WashingtonOTHER | 1 | Sep 24, 2026 | clinicaltrials |
| NCT06213311 | A Study of Axicabtagene Ciloleucel and Glofitamab as Second-Line Therapy for Relapsed or Refractory Patients With Large B Cell Lymphoma | recruiting | Phase 2 | 40 | M.D. Anderson Cancer CenterOTHER | 1 | Sep 24, 2026 | clinicaltrials |
| NCT06290687 | Partial Cystectomy & Extended Pelvic Lymph Node Dissection With SOC Perioperative Systemic Therapy | withdrawn | Phase 2 | 0 | Case Comprehensive Cancer CenterOTHER | 0 | Sep 24, 2026 | clinicaltrials |
| NCT06462222 | Immune Checkpoint Inhibitor Combined With Pemetrexed Intrathecal Injection for Leptomeningeal Metastasis From Solid Tumors | active not recruiting | Phase 1 / Phase 2 | 45 | Guangzhou Medical UniversityOTHER | 1 | Sep 24, 2026 | clinicaltrials |
| NCT06660654 | A Study of Raludotatug Deruxtecan in Participants With Advanced/Metastatic Solid Tumors (REJOICE-PanTumor01) | active not recruiting | Phase 2 | 335 | Daiichi SankyoINDUSTRY | 9 | Sep 24, 2026 | clinicaltrials |
| NCT06693336 | An Adjuvant Study to Evaluate SMS001 (Paclitaxel) in Non-Small Cell Lung Cancer | recruiting | Phase 2 | 42 | ToLymph Inc.INDUSTRY | 2 | Sep 24, 2026 | clinicaltrials |
| NCT06836726 | Clinical Trial to Test Efficacy of Targeting Hypoxia Combined With ARSI After First-line ARSI Therapy for Castrate Resistant Prostate Cancer(EVO) | not yet recruiting | Phase 2 | 35 | University Health Network, TorontoOTHER | 1 | Sep 24, 2026 | clinicaltrials |
| NCT07069712 | A Study of Novel Agents or Combinations as Perioperative Treatment in Participants With Locally Advanced Resectable Gastroesophageal Adenocarcinoma | recruiting | Phase 2 | 100 | AstraZenecaINDUSTRY | 11 | Sep 24, 2026 | clinicaltrials |
| NCT07407920 | Ph2 Study for Optimization of Adjunct Systemic Therapy in HER2+ Patients, MolecularPCR Trial | recruiting | Phase 2 | 120 | M.D. Anderson Cancer CenterOTHER | 1 | Sep 24, 2026 | clinicaltrials |
| NCT07438626 | Phase II Trial of Sacituzumab Tirumotecan in Patients With SMARCB1-Deficient Renal Medullary Carcinoma | recruiting | Phase 2 | 20 | M.D. Anderson Cancer CenterOTHER | 1 | Sep 24, 2026 | clinicaltrials |
| NCT07548450 | Mosunetuzumab in Combination With Pirtobrutinib in Patients With Relapsed or Refractory Waldenstrom Macroglobulinemia (MPOWER)(MPOWER) | not yet recruiting | Phase 2 | 25 | University of UtahOTHER | 1 | Sep 24, 2026 | clinicaltrials |
| NCT07559929 | A Study of DXC006 With Immune Checkpoint Inhibitors or Platinum for Small Cell Lung Cancer. | recruiting | Phase 1 / Phase 2 | 200 | Hangzhou DAC Biotechnology Co., Ltd.INDUSTRY | 1 | Sep 24, 2026 | clinicaltrials |
| NCT07594015 | Pembrolizumab and Lenvatinib in Mismatch Repair Proficient Recurrent Endometrial Cancer After Progression on or Following First-Line Immunotherapy Maintenance | recruiting | Phase 2 | 46 | University of MiamiOTHER | 1 | Sep 24, 2026 | clinicaltrials |
| NCT07621614 | A Study on How to Safely Guide Surgery for Melanoma and Similar Skin Tumors in Children Using Pathology and Genetic Information | recruiting | Phase 2 | 51 | Children's Oncology GroupNETWORK | 1 | Sep 24, 2026 | clinicaltrials |
| NCT07722754 | Bevacizumab, Sintilimab, Cetuximab and Irinotecan in Refractory RAS Wild-type Metastatic Colorectal Cancer: BOND-4 Trial(BOND-4) | recruiting | Phase 2 | 160 | Guangdong Provincial People's HospitalOTHER | 1 | Sep 24, 2026 | clinicaltrials |
| NCT07800507 | Trop2-Targeted Near-Infrared Fluorescence Imaging-Guided Precise Resection of Non-Muscle Invasive Bladder Cancer | not yet recruiting | Phase 1 / Phase 2 | 30 | Yunnan Cancer HospitalOTHER | 1 | Sep 24, 2026 | clinicaltrials |
| NCT07838753 | A Study Testing if Patients With Advanced Prostate Cancer Who Are Responding Well to Combination Treatment Can Safely Reduce Their Medication to a Single Hormone Therapy, Compared to Continuing Their Current Drugs(STEPDOWNmHSPC) | not yet recruiting | Phase 2 | 170 | Kokilaben Dheerubhai Ambani Hospital and ResearchUNKNOWN | 1 | Sep 24, 2026 | clinicaltrials |
| NCT07839819 | Study of PM54 in Combination With Cytotoxic and Targeted Agents in Adult Participants With Advanced Malignancies | not yet recruiting | Phase 1 / Phase 2 | 231 | PharmaMarINDUSTRY | 4 | Sep 24, 2026 | clinicaltrials |
| NCT07840001 | Neoadjuvant Belzutifan Plus Pembrolizumab in High-Risk, Locally Advanced Clear Cell Renal Cell Carcinoma(NEBULA) | not yet recruiting | Phase 2 | 30 | Peter MacCallum Cancer Centre, AustraliaOTHER | 1 | Sep 24, 2026 | clinicaltrials |
| NCT02392429 | FLT PET/CT in Measuring Response in Patients With Previously Untreated Acute Myeloid Leukemia | active not recruiting | Phase 2 | 87 | National Cancer Institute (NCI)NIH | 1 | Sep 23, 2026 | clinicaltrials |
| NCT02650401 | Study Of Entrectinib (Rxdx-101) in Children and Adolescents With Locally Advanced Or Metastatic Solid Or Primary CNS Tumors And/Or Who Have No Satisfactory Treatment Options(STARTRK-NG) | active not recruiting | Phase 1 / Phase 2 | 69 | Hoffmann-La RocheINDUSTRY | 9 | Sep 23, 2026 | clinicaltrials |
| NCT03015896 | Nivolumab and Lenalidomide in Treating Patients With Relapsed or Refractory Non-Hodgkin or Hodgkin Lymphoma | completed | Phase 1 / Phase 2 | 36 | David Bond, MDOTHER | 1 | Sep 23, 2026 | clinicaltrials |
| NCT03174197 | Atezolizumab in Combination With Temozolomide and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma | completed | Phase 1 / Phase 2 | 60 | M.D. Anderson Cancer CenterOTHER | 1 | Sep 23, 2026 | clinicaltrials |
| NCT03367676 | 12 weekS Adjuvant dOcetaxel Plus trastuzumaB in Patients With Small, Node-negative, HER2-positive Breast cancER (SOBER)(SOBER) | terminated | Phase 2 | 78 | Ruijin HospitalOTHER | 1 | Sep 23, 2026 | clinicaltrials |
| NCT03381274 | Oleclumab (MEDI9447) Epidermal Growth Factor Receptor Mutant (EGFRm) Non-small Cell Lung Cancer (NSCLC) Novel Combination Study | active not recruiting | Phase 1 / Phase 2 | 43 | MedImmune LLCINDUSTRY | 3 | Sep 23, 2026 | clinicaltrials |
| NCT03463057 | The Feasibility and Clinical Efficacy of Atezolizumab Consolidation Treatment in High Risk (IPI > 2) DLBCL(HO151DLBCL) | active not recruiting | Phase 2 | 109 | Stichting Hemato-Oncologie voor Volwassenen NederlandOTHER | 2 | Sep 23, 2026 | clinicaltrials |
| NCT03899155 | Pan Tumor Rollover Study | recruiting | Phase 2 | 1,500 | Bristol-Myers SquibbINDUSTRY | 38 | Sep 23, 2026 | clinicaltrials |
| NCT04062708 | CHIO3 Trial: CHemotherapy Combined With Immune Checkpoint Inhibitor for Operable Stage IIIA/B Non-Small Cell Lung Cancer | active not recruiting | Phase 2 | 38 | Alliance Foundation Trials, LLC.OTHER | 1 | Sep 23, 2026 | clinicaltrials |
| NCT04266795 | A Study of Pevonedistat and Venetoclax Combined With Azacitidine to Treat Acute Myeloid Leukemia (AML) in Adults Unable to Receive Intensive Chemotherapy(PEVENAZA) | completed | Phase 2 | 164 | TakedaINDUSTRY | 5 | Sep 23, 2026 | clinicaltrials |
| NCT04684368 | A Study of a New Way to Treat Children and Young Adults With a Brain Tumor Called NGGCT | recruiting | Phase 2 | 160 | Children's Oncology GroupNETWORK | 4 | Sep 23, 2026 | clinicaltrials |
| NCT04715958 | SHAPE Neoadjuvant Chemotherapy Response | active not recruiting | Phase 2 / Phase 3 | 122 | Kibo NamOTHER | 1 | Sep 23, 2026 | clinicaltrials |
| NCT04729959 | Testing the Addition of the Immune Therapy Drugs, Tocilizumab and Atezolizumab, to Radiation Therapy for Recurrent Glioblastoma | active not recruiting | Phase 2 | 61 | National Cancer Institute (NCI)NIH | 1 | Sep 23, 2026 | clinicaltrials |
| NCT04910685 | (HARBOR) Study to Evaluate Efficacy and Safety of BLU-263 Versus Placebo in Patients With Indolent Systemic Mastocytosis | recruiting | Phase 2 / Phase 3 | 534 | Blueprint Medicines CorporationINDUSTRY | 23 | Sep 23, 2026 | clinicaltrials |
| NCT05061550 | Neoadjuvant and Adjuvant Treatment in Resectable Non-small Cell Lung Cancer(NeoCOAST-2) | recruiting | Phase 2 | 630 | AstraZenecaINDUSTRY | 12 | Sep 23, 2026 | clinicaltrials |
| NCT05290194 | Radiotherapy Combined With PD-1 Monoclonal Antibody and Capecitabine in the Treatment of Nasopharyngeal Carcinoma | withdrawn | Phase 2 | 0 | Fifth Affiliated Hospital, Sun Yat-Sen UniversityOTHER | 1 | Sep 23, 2026 | clinicaltrials |
| NCT05312840 | Efficacy and Safety of Conventional and Low-dose Platinum Gemcitabine Combined With Sintilimab With Delayed Administration in First-line Treatment of Advanced Squamous Non-small Cell Lung Cancer | completed | Phase 2 | 20 | People's Hospital of QuzhouOTHER | 1 | Sep 23, 2026 | clinicaltrials |
| NCT05320198 | Study of DISC-0974 (RALLY-MF) in Participants With Myelofibrosis or Myelodysplastic Syndrome and Anemia | recruiting | Phase 1 / Phase 2 | 150 | Disc Medicine, IncINDUSTRY | 2 | Sep 23, 2026 | clinicaltrials |
| NCT05332002 | sFOLFOXIRI in Advanced Gastroesophageal Cancer, (SAGE) | recruiting | Phase 2 | 38 | Rutgers, The State University of New JerseyOTHER | 1 | Sep 23, 2026 | clinicaltrials |
| NCT05333458 | Testing Atezolizumab With Selinexor in People ≥ 12 Years Old With Alveolar Soft Part Sarcoma, AXIOM Trial | recruiting | Phase 2 | 27 | National Cancer Institute (NCI)NIH | 1 | Sep 23, 2026 | clinicaltrials |
| NCT05360160 | A Phase I-II Study Investigating the All-Oral Combination of the Menin Inhibitor SNDX-5613 With Decitabine/Cedazuridine (ASTX727) and Venetoclax in Acute Myeloid Leukemia (SAVE) | recruiting | Phase 1 / Phase 2 | 43 | M.D. Anderson Cancer CenterOTHER | 1 | Sep 23, 2026 | clinicaltrials |
| NCT05489211 | Study of Dato-DXd as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Tumours (TROPION-PanTumor03) | recruiting | Phase 2 | 454 | AstraZenecaINDUSTRY | 14 | Sep 23, 2026 | clinicaltrials |
| NCT05607108 | A Study of ZEN003694 in People With Squamous Cell Lung Cancer | recruiting | Phase 2 | 13 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Sep 23, 2026 | clinicaltrials |
| NCT05645718 | Study of Pedi-cRIB: Mini-Hyper-CVD With Condensed Rituximab, Inotuzumab Ozogamicin and Blinatumomab (cRIB) for Relapsed Therapy for Pediatric With B-Cell Lineage Acute Lymphocytic Leukemia | recruiting | Phase 2 | 27 | M.D. Anderson Cancer CenterOTHER | 1 | Sep 23, 2026 | clinicaltrials |
Data updated 6 days agoSource updated Sep 24, 2026source: clinicaltrials